for people ages up to 120 years (full criteria)
Healthy Volunteers
healthy people welcome
at San Francisco, California
study started
completion around
Principal Investigator
by Jinoos Yazdany, MD
Headshot of Jinoos Yazdany
Jinoos Yazdany



Hydroxychloroquine (HCQ) is a disease-modifying, anti-rheumatic drug that regulates immune system activity and is typically prescribed to treat rheumatoid arthritis and systemic lupus erythematosus, as well as other immune conditions. Although generally well tolerated, study data have demonstrated that long-term use of HCQ may lead to irreversible and potentially vision-threatening retinal toxicity. The American Academy of Ophthalmology (AAO) issued guidelines in 2011, and again in 2016 that recommended dosing of HCQ be based on an individual's body weight, and also outlined how and when to screen for retinal toxicity. While clinicians have been aware of the potential side effects of HCQ for decades, studies have shown that many patients continue to receive higher than recommended doses.

The goal of this study is to conduct a pragmatic trial to assess the utility of a new e-prescribing (eRX) interface for prescriptions of hydroxychloroquine (HCQ). The investigators will measure the effectiveness of the system in reducing the number of individuals prescribed HCQ over current guidelines by randomizing clinicians to the new interface. Ideally, the eRX interface will result in a lower number of potential adverse events (i.e. retinal toxicity) associated with high-dose, long-term use of HCQ.

Official Title

A Quality Improvement Study to Measure the Effectiveness of an E-prescribing Interface to Reduce Dosage of Hydroxychloroquine Above Current Guidelines


Rheumatic Diseases, Collagen Diseases, New e-prescribing interface, New eRX Interface


You can join if…

Open to people ages up to 120 years

  • All providers that prescribed hydroxychloroquine in the year previous to the intervention start date in rheumatology and dermatology clinics

You CAN'T join if...

  • Inactive providers in rheumatology and dermatology clinics


  • UCSF
    San Francisco California 94143 United States

Lead Scientist at UCSF

  • Jinoos Yazdany, MD
    Dr. Yazdany is Chief of the Division of Rheumatology at Zuckerberg San Francisco General Hospital (ZSFG) and the Alice Betts Endowed Professor of Medicine at UCSF. She received her undergraduate degree from Stanford, her MD from UCLA, and her MPH from Harvard. She joined the faculty after completing internal medicine residency and fellowship in rheumatology at UCSF.


in progress, not accepting new patients
Start Date
Completion Date
University of California, San Francisco
Study Type
About 65 people participating
Last Updated